Clinical Trials
58 trialsTesting the Addition of Targeted Radiation Therapy to Surgery and the Usual Chemotherapy Treatment (Pemetrexed and Cisplatin [or Carboplatin]) for Stage I-IIIA Malignant Pleural Mesothelioma
NRG Oncology
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
Sotio Biotech Inc.
MESO-PRIME
Royal Marsden NHS Foundation Trust
A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
Takeda
A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma
Dana-Farber Cancer Institute
BIMES
Fundación GECP
KZR-261 in Subjects With Advanced Solid Malignancies
Kezar Life Sciences, Inc.
Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors
Incyte Corporation
MK-3475-A17
Merck Sharp & Dohme LLC
Phase I Dose-Escalation Study Of Azacitidine In Combination With Temozolomide
Columbia University
Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels
Ipsen
A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors
Deciphera Pharmaceuticals, LLC
Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma
Canadian Cancer Trials Group
PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors
Pfizer
Pevonedistat Alone and in Combination With Chemotherapy in Patients With Mesothelioma
Memorial Sloan Kettering Cancer Center
CheckMate743
Bristol-Myers Squibb
Window of Opportunity Study of VS-6063 (Defactinib) in Surgical Resectable Malignant Pleural Mesothelioma Participants
Verastem, Inc.
Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma
National Institutes of Health Clinical Center (CC)
A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal Mesothelioma
University of Chicago
Early Palliative Care in Advanced Lung and Gastrointestinal Malignancies
Massachusetts General Hospital
ATOMIC
Polaris Group
A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)
University of Florida
A Clinical Study of Anetumab Ravtansine in Adults With Solid Tumors Who Have Been Treated in Previous Bayer-sponsored Anetumab Ravtansine Studies
Bayer
PrE0505
PrECOG, LLC.
Pemetrexed Plus Gemcitabine or Carboplatin for Patients With Advanced Malignant Pleural Mesothelioma
Eastern Cooperative Oncology Group
Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma
M.D. Anderson Cancer Center
MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma
Baylor College of Medicine
A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
Mesothelin-Targeted Immunotoxin LMB-100 in People With Malignant Mesothelioma
National Institutes of Health Clinical Center (CC)
Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases
National Institutes of Health Clinical Center (CC)
Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.
Novartis
Anti-Mesothelin Immunotoxin LMB-100 Followed by Pembrolizumab in Malignant Mesothelioma
National Institutes of Health Clinical Center (CC)
INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
Incyte Corporation
Study of the EZH2 Inhibitor Tazemetostat in Malignant Mesothelioma
Epizyme, Inc.
Olaparib in People With Malignant Mesothelioma
National Institutes of Health Clinical Center (CC)
Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM)
Bayer
MK-0683-014
Merck Sharp & Dohme LLC
Cisplatin, Pemetrexed and Bevacizumab for Untreated Malignant Mesothelioma
University of Texas Southwestern Medical Center
Probe Based Confocal Laser Endomicroscopy During Thoracoscopy for Pleural Malignancies Diagnosis.
University of Liege
Mithramycin for Lung, Esophagus, and Other Chest Cancers
National Institutes of Health Clinical Center (CC)
Mesothelin-Targeted Immunotoxin LMB-100 in Combination With SEL-110 in Subjects With Malignant Pleural or Peritoneal Mesothelioma
National Institutes of Health Clinical Center (CC)
Eloxatin® Plus Gemcitabine Chemotherapy for Mesothelioma
Columbia University
CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer
National Institutes of Health Clinical Center (CC)
Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy
Mayo Clinic
SIGNATURE
Novartis
SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma
National Institutes of Health Clinical Center (CC)
Nintedanib (BIBF 1120) in Mesothelioma
Boehringer Ingelheim
18F-FSPG PET/CT for Cancer Patients on Therapy
Stanford University